CombiGene AB (publ) announced that the Company has entered into a license agreement with Spark Therapeutics to certain intellectual property developed or used by Spark in connection with the Prior License Agreement for CGO1. Through the license agreement, Spark is eligible to receive a low single digit percentage in royalties on future net sales of Licensed Products. The license agreement assures that CombiGene can use data and inventions and secures critical rights which will facilitate CombiGene's efforts in finding a new partner for the epilepsy project.

According to the agreement, CombiGene will not make any up-front or milestone payments for the license. The Company and Spark previously collaborated to develop CG01, a gene therapy that express the human neuropeptide Y (NPY) and its receptor Y2 (NPY2R). The Company regained global rights to CGO1 in January 2024 following the termination period of the collaboration and license agreement between the two companies.

Spark will share data from past and current ongoing studies at the latest by early Fourth Quarter-2024. Through the license agreement, CombiGene will receive the data from these important studies.